Brisbane, February 2018
Now eye care professionals can take a proactive, preventative approach to the growing global problem of age-related macular degeneration (AMD).
Measuring macular pigment optical density (MPOD) – a significant and modifiable risk factor for AMD – the MPS II provides results at speeds as fast as 90 seconds per eye.
“The MPS II is the quickest, most affordable, and most clinically relevant ophthalmic device in the world. It provides an efficient method for determining macular pigment optical density in everyday optometric and ophthalmological practice. I believe it will revolutionise the practice of eye care.“ Stuart P. Richer, OD, PhD, Director, Ocular Preventive Medicine, Captain James A Lovell Federal Healthcare Facility, Chicago, USA.
Age-related macular degeneration (AMD) is a growing global socioeconomic threat, but there are ways to prevent or mitigate its impact. By adopting a proactive approach to fighting the condition, eye care professionals can identify and help those most at risk before more serious intervention is necessary.
The Macular Pigment Screener (MPS II) is a key enabler in such an approach. It helps patients by identifying and monitoring macular pigment levels over time and supports professionals with the diversification of eye health services.